ReviewVirology journal2026
CD163 at the crossroads: a viral-exploited immunomodulator.
Review in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CRISPR-based screening of host factors in veterinary viral infections: from target discovery to host-directed antiviral strategies.Frontiers in veterinary science · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Porcine reproductive and respiratory syndrome virus (PRRSV) is a major pathogen in pigs and poses a significant economic threat to the pig industry. CD163 acts as a key cellular receptor for PRRSV infection, mediating viral entry into host cells. Beyond functioning as a viral entry factor, CD163 plays multifaceted roles in PRRSV infection by linking viral pathogenesis with host immune regulation. This review summarizes current understanding of CD163's structure, physiological functions, mechanisms in PRRSV entry, and immunomodulatory roles during infection. We explore how CD163 expression and ectodomain shedding influence macrophage polarization and cytokine dynamics, thereby shaping viral persistence and tissue injury. Key evidence indicates that PRRSV harnesses anti-inflammatory signaling to sustain CD163 expression and promote entry, whereas pro-inflammatory stimuli downregulate CD163 and restrict replication. Shed soluble CD163 (sCD163) exhibits dual functions: it can act as a decoy receptor to mitigate viral spread, yet may also exacerbate inflammatory pathology. We also review recent advances in CD163-targeted interventions, including gene-edited pigs resistant to PRRSV, neutralizing antibodies, and small-molecule inhibitors that disrupt CD163-virus interactions. Critical analysis supports that targeted deletion or modification of CD163 confers viral resistance without impairing its essential physiological functions. In summary, CD163 functions not only as a gateway for PRRSV entry but also as an immunomodulator influencing disease outcomes. Elucidating this duality provides new perspectives for developing control strategies that combine effective viral blockade with the maintenance of immune homeostasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.